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Abstract Subfebrile temperature or fever is present in
about a third of patients on the first day after stroke onset
and is associated with poor outcome. However, the tem-
poral profile of this association is not well established. We
aimed to assess the relationship between body temperature
on admission as well as the change in body temperature
from admission to 24 h thereafter and functional outcome
and death. We analyzed data of 1,332 patients admitted
within 12 h of stroke onset. The relation between body
temperature on admission or the change in body tempera-
ture from admission to 24 h thereafter (adjusted for body
temperature on admission) on the one hand and unfavor-
able outcome (death, or a modified Rankin Scale score [2)
at 3 months on the other were expressed as odds ratio per
1.0C increase in body temperature. Adjustments for
potential confounders were made with a multiple logistic
regression model. No relation was found between
admission body temperature and poor outcome (aOR 1.06;
95% CI 0.85–1.32) and death (aOR 1.23; 95% CI
0.95–1.60). In contrast, increased body temperature in the
first 24 h after stroke onset was associated with poor out-
come (aOR 1.30; 95% CI 1.05–1.63) and death (aOR 1.51;
95% CI 1.15–1.98). An early rise in body temperature
rather than high body temperature on admission is a risk
factor for unfavorable outcome in patients with acute
stroke.
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Background
Subfebrile temperature or fever is common in patients with
acute stroke. Body temperatures over 37.5C have been
reported in up to a quarter of patients within the first 6 h
[19], and in about a third at 24 h after stroke onset [7]. This
elevation of body temperature may be a direct consequence
of brain damage inflicted by stroke, or a result of an
associated infection [8].
Increased body temperature markedly exacerbates neu-
ronal injury in experimental models of cerebral ischemia
[13]. An association between increased body temperature
and poor outcome has also been shown in patients with
acute stroke [3, 4, 7, 12, 14–17, 19–21, 23]. However, the
temporal profile of this relation is not well established.
Several prospective studies found that high body temper-
ature on admission was associated with poor outcome [3, 7,
16, 19, 20, 23]. Others found that an increased body tem-
perature within the first days after stroke onset was a
prognostic factor for unfavorable outcome [4, 12, 20, 21].
The aim of our study was to assess the relationship
between body temperature within the first 12 h after
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symptom onset, and the change in body temperature from
admission to 24 h thereafter on the one hand, and func-
tional outcome and death on the other, in a large sample of
stroke patients.
Methods
All patients participated in the Paracetamol (Acetamino-
phen) In Stroke (PAIS) trial. The PAIS trial was a multi-
center, randomized, placebo-controlled clinical trial of
high-dose acetaminophen in patients with acute stroke [10].
In short, patients with ischemic stroke or intracerebral
hemorrhage with no history of liver disease or significant
pre-stroke impairment (grade on the modified Rankin Scale
(mRS) C2) [22] were included within 12 h of symptom
onset and treated with high-dose acetaminophen (6 g daily)
or placebo for the next 3 days.
Clinical characteristics
Baseline clinical information included stroke severity
assessed by means of the NIH Stroke Scale (NIHSS [6]),
ischemic stroke subtype according to the TOAST classifi-
cation [2], and cardiovascular risk factors. In addition, any
infection that led to prolonged hospital stay or was life
threatening was recorded. The diagnosis of infection was
left with the treating physician.
Body temperature
Body temperature was measured with a tympanic or rectal
thermometer within 12 h from stroke onset and 24 h later.
In each patient, a similar method of thermometry was used
at these two points in time.
Outcome measures
Poor outcome was defined as a grade of more than two on
the mRS at 3 months from stroke onset. Scores on the mRS
range from 0 (no symptoms at all) to 5 (severe disability);
for statistical purposes, death has a score of six.
A secondary outcome measure was death at 3 months.
Outcome assessment was blinded for body temperature.
Statistical analysis
Statistical analyses were performed with Stata/SE 9.2 for
Windows (Statacorp, College Station, TX, USA). The
relation between body temperature on admission and the
change in body temperature from admission to 24 h
thereafter (adjusted for admission body temperature) on the
one hand and poor outcome or death on the other, was
expressed as an odds ratio per 1.0C increase in body
temperature with a corresponding 95% confidence interval
(CI), as estimated with logistic regression.
Adjustments were made with a multiple logistic
regression model that included the following factors: age,
sex, baseline NIHSS score, stroke type (ischemic stroke vs.
intracerebral hemorrhage), ischemic stroke subtype (lacu-
nar vs. non-lacunar infarction), treatment with rtPA, and
the occurrence of infections. We performed additional
analyses to account for the potential confounding effect of
antipyretic treatment by stratifying for treatment with
acetaminophen, which was the experimental drug treatment
in the PAIS trial.
Furthermore, we assessed the relation between several
clinical variables including stroke type, ischemic stroke
subtype, and stroke severity (expressed in quartiles of the
baseline NIHSS score) and the change in body temperature
from baseline to 24 h thereafter (adjusted for admission
body temperature) with multiple linear regression.
Results
Included into the PAIS trial were 1,400 patients with a
clinical diagnosis of ischemic stroke or intracerebral
hemorrhage. Of these patients, 68 were excluded from the
present study either because the final diagnosis was not a
stroke (n = 3) or because body temperature at 24 h was
not recorded (n = 65).
In the remaining 1,332 patients, mean age was 70 years
(SD 13), 56% of the patients were male, and 88% had an
ischemic stroke (Table 1). The infarction was of the lacu-
nar type in 193 patients (17%). The median score on the
NIHSS scale was 6 (range 0–30). Median time from stroke
onset to measurement of the admission body temperature
was 6 h (IQR 240–540). A total of 660 patients (50%) was
treated with acetaminophen.
The mean body temperature was 36.9C (SD 0.6) on
admission, and 37.1C (SD 0.7) 24 h later. Body tem-
perature over 37.5C was observed in 160 patients (12%)
on admission and in 298 (22%) 24 h later. The increase in
body temperature from baseline to 24 h thereafter was
larger in patients with body temperatures of 37.0C or
less than in those with body temperatures over 37.0C
(Fig. 1).
After 24 h, 96 of 660 patients (15%) treated with acet-
aminophen and 202 of 672 patients (30%) on placebo had a
body temperature over 37.5C (difference 15%; 95% CI
11–19%). Treatment with acetaminophen was associated
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with a 0.26C (95% CI, 0.18–0.31) reduction in mean body
temperature measured 24 h after admission.
Four of the 160 patients (3%) with baseline body tem-
peratures over 37.5C and 24 of 298 patients (8%) with
body temperatures over 37.5C 24 h later developed an
infection during hospitalization.
The proportion of patients with admission body tem-
peratures over 37.5C was similar in patients with ischemic
stroke [145/1,169 (12%) [and in those with intracerebral
hemorrhage [16/163 (10%)] and also in patients with non-
lacunar infarction [136/1,139 (10%)] and lacunar infarction
[24/193 (12%)]. However, the increase in body temperature
from admission to 24 h thereafter was 0.24C larger (95%
CI, 0.14–0.33) in patients with non-lacunar infarction than
in those with lacunar infarction and also 0.33C (95% CI,
0.23–0.44) larger in patients with intracerebral hemorrhage
than in patients with ischemic stroke.
We did not observe a proportional increase in the
association between stroke severity and body temperature
on admission. However, in the highest quartile of the NI-
HSS score (NIHSS score C13), baseline body temperature
was 0.20C (95% CI, 0.12–0.27) lower than body tem-
perature in the lower quartiles of the NIHSS score (NI-
HSS \13) (Fig. 2). Body temperature 24 h later was
associated with baseline stroke severity. For every quartile
of the NIHSS score, body temperature at 24 h rose on
average with 0.16C (95% CI, 0.13–0.19) (Fig. 2).
Body temperature on admission was not related to poor
outcome or death (Table 2). An increased body tempera-
ture in the first 24 h after admission, however, was asso-
ciated with poor outcome or death at 3 months (Table 2).
Adjustment for potential confounders slightly attenuated
this association (Table 2). An additional stratified analysis
to account for the potentially modifying effect of treatment
Fig. 1 The change in body temperature in the first 24 h from
admission to 24 h thereafter (8C) as a function of body temperature on
admission (8C)
Table 1 Baseline clinical characteristics of the patients (n = 1,332)
Demographics
Mean (SD) age (years) 70 (13)
Sex (male) 749 (56%)
Cardiovascular risk factors
Hypertension 652 (49%)
Atrial fibrillation 198 (15%)
Diabetes mellitus 195 (15%)




Myocardial infarction 155 (12%)
Peripheral vascular disease 128 (10%)
Stroke type
Ischemic stroke 1,169 (88%)
Ischemic stroke subtypea
Large vessel disease (C50% stenosis) 146 (12%)
Cardiac source of embolism 216 (18%)
Small vessel occlusion 193 (17%)
Other determined etiology 90 (8%)
Undetermined 477 (41%)
Missing information 47 (4%)
Stroke severity
Median (range) NIHSS scoreb 6 (0–30)
Physical examination
Mean (SD) body temperature (C) 36.9 (0.6)
Median (IQR) time from stroke onset





Intravenous alteplase 281 (21%)
a Based on the trial of ORG 10172 in Acute Stroke Therapy
(TOAST) criteria
b Scores on the National Institutes of Health Stroke Scale (NIHSS)
Fig. 2 Stroke severity (quartiles) and body temperature within 12 h
from stroke onset, (grey bars) and 24 h later (black bars)
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with acetaminophen did not affect the association
(Table 2).
After exclusion of patients who developed an infection
during the first 2 weeks after stroke onset, the adjusted
odds ratio for poor outcome was 1.30 (95% CI 1.04–1.63),
and for death 1.50 (95% CI 1.12–2.00).
Figure 3 illustrates the strength of the association
between the change in body temperature from admission to
24 h thereafter and poor outcome. The absolute difference
in the risk of poor outcome between patients in the lowest
and patients in the highest body temperature category is
more than 20%.
Discussion
Our results do not confirm the previously reported associ-
ation between high body temperature on admission and
unfavorable outcome in patients with acute stroke. How-
ever, patients with increased body temperatures in the first
24 h after admission did have an increased risk of poor
functional outcome or death at 3 months.
Before these results can be interpreted, some methodo-
logical issues have to be discussed. First, one of the
strengths of our study is its large sample size. Other
strengths include robust outcome measures and detailed
information on confounders. Second, PAIS was a ran-
domized double-blind placebo-controlled trial that
addressed the question of whether temperature reduction
by acetaminophen would improve outcome in patients with
acute stroke [10]. Half of the study population was treated
with acetaminophen in a daily dose of 6 g for three con-
secutive days. As a result, body temperature at 24 h after
admission was lowered and fewer patients may have
experienced a poor outcome, although the overall effect of
acetaminophen on outcome was not statistically significant.
We did separate regression analyses in the patients treated
with acetaminophen and those allocated to placebo. The
estimates of the association between the change in body
temperature from admission to 24 h thereafter and outcome
were similar in the two groups, suggesting that the study
population could be analyzed as one group.
A third issue is that we only recorded body temperature
at two points in time, i.e., within 12 h from symptom onset
and 24 h later and did not repeat measurements of body
temperature. As a consequence, it might be more difficult
to compare our results with the results of previous studies.
Finally, relatively few patients with very severe stroke
were included, possibly because we did not specify a lower
NIHSS score limit in the eligibility criteria of the PAIS
trial. However, our results showed that patients with more
severe strokes had higher body temperatures at 24 h after
admission, and thereby underrepresentation of patients
with severe strokes potentially weakens rather than exag-
gerates the observed relation between body temperature at
24 h after admission and poor outcome.
Previous studies have found that increased body temper-
ature within 6 h up to at least 24 h after stroke onset is an
independent prognostic factor for poor outcome [3, 4, 7, 12,
14–17, 19–21, 23]. However, the temporal profile of this
association is still under debate. Several studies showed that
Table 2 Association of body temperature with poor outcome or death at 3 months
Poor outcome Overall Overall aOR (95% CI)ab
OR (95% CI)a aOR (95% CI)ab Acetaminophen Placebo
Within 12 h from stroke onset mRS [2 (n = 663) 0.82 (0.68–0.98) 1.06 (0.85–1.32) 0.91 (0.66–1.26) 1.19 (0.87–1.64)
Death (n = 218) 0.87 (0.68–1.12) 1.23 (0.95–1.60) 1.10 (0.74–1.63) 1.37 (0.96–1.96)
Change from admission to 24 hc mRS [2 (n = 663) 1.98 (1.65–2.39) 1.30 (1.05–1.63) 1.22 (0.86–1.73) 1.35 (1.00–1.83)
Death (n = 218) 2.36 (1.86–2.99) 1.51 (1.15–1.98) 1.51 (0.97–2.36) 1.61 (1.11–2.31)
a Per 1.0 Celsius increase of body temperature
b Adjusted for age, sex, NIHSS score, stroke type, ischemic stroke subtype, treatment with rtPA, and occurrence of infections
c Adjusted for body temperature on admission
Fig. 3 Probability of poor outcome (mRS [2) at 3 months in relation
to change in body temperature from baseline to 24 h thereafter
(sixtiles) (8C)
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high body temperature on admission was associated with
poor outcome [3, 7, 15]. In three of these, no adjustments
were made for baseline stroke severity assessed with vali-
dated stroke scales [2, 5, 8]. In a prospective study of 390
patients with either ischemic stroke or intracerebral hemor-
rhage admitted within 6 h of symptom onset, the odds of poor
outcome doubled for every degree of Celsius increase in
baseline body temperature [19]. We found that patients with
severe stroke had relatively low body temperatures at base-
line, possibly because of a faster loss of body temperature
before hospital admission as a result of less muscle activity.
This finding might explain in part that body temperature on
admission was not associated with clinical outcome.
A prospective study of 725 patients admitted within 6 h
of symptom onset found a relation between increased body
temperature at 10–12 h after stroke onset and poor outcome,
but no relationship between body temperature on admission
and poor outcome was found [4]. Although these results
seem contradictory to our findings, our results indeed sug-
gest that increased body temperature in the first 24 h after
admission rather than body temperature on admission is an
important prognostic factor for clinical outcome after
stroke. In line with our results, a recent study of 5,305
patients with ischemic stroke from the Virtual International
Stroke Trials Archive found that an increase in body tem-
perature from baseline rather than high body temperature on
admission was a strong risk factor for poor outcome [20].
As the data came from different randomized trials, body
temperature was dichotomized at 37.2C and follow-up
temperatures were only available for a third of the patients.
Two others showed that increased body temperature
relative to baseline in the first 24–72 h after stroke onset
was associated with unfavorable outcome [12, 21]. These
studies included only patients with intracerebral hemor-
rhage [21] or patients with ischemic stroke treated with
intravenous thrombolysis [12].
In a recent prospective study with 250 patients with
ischemic stroke, the association between body temperature
and unfavorable outcome was dependent on treatment with
alteplase [17]. High body temperature in the first 6 h from
symptom onset was associated with favorable outcome in
patients treated with alteplase, and low body temperature
was associated with favorable prognosis in those not trea-
ted with alteplase. In the present study, we could not
confirm that the association between body temperature and
outcome is dependent on treatment with rtPA.
Increased body temperature may be attributed to a sys-
temic inflammatory response following ischemic stroke or
to accompanying infections. In addition, it has been sug-
gested that increased body temperature indicates hypotha-
lamic damage following stroke [18]. The mechanisms of the
association between an early rise in body temperature and
poor outcome remain speculative. Secondary infections are
common in the first week of stroke and are associated with
poor outcome, but they usually occur more than 12 h after
stroke onset [11]. In our study, only 8% of patients with
body temperatures over 37.5C developed an infection
during hospitalization. Besides, the relationship between
body temperature at 24 h after admission and poor outcome
was independent of the occurrence of infections. Further-
more, exclusion of patients developing an early infection
during hospitalization did not substantially affect the rela-
tion between body temperature and poor functional out-
come or death. Therefore, infections cannot account for the
observed relation between temperature and outcome.
The change in body temperature from admission was
associated with baseline stroke severity. One may argue
that increased body temperature does not accelerate the
ischemic cascade, but merely reflects extensive cerebral
damage and, thereby, of poor outcome. However, the
relation between increased body temperature and poor
outcome was independent of baseline stroke severity.
Our results provide a rationale for the hypothesis that
prevention of an early rise in body temperature could
reduce death and improve functional outcome. Guidelines
for the treatment of patients with acute ischemic stroke [1]
or intracerebral hemorrhage [5] recommend the adminis-
tration of antipyretic medication in case of fever or a
temperature above 37.5C. This might be too late, as the
rise in body temperature has already occurred, and the time
period in which the brain lesion is most vulnerable has
subsided. On the other hand, there is still no convincing
evidence from randomized trials that strategies to prevent
or treat elevated body temperature reduce case fatality and
improve functional outcome after stroke [9, 10].
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